Funding Opportunity RFA-DA-22-036 from the NIH Guide for Grants and Contracts. In April 2018, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-termSMInitiative or HEAL InitiativeSM, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Through this initiative the National Institute on Drug Abuse, in partnership with other NIH Institutes, Centers, and Offices, requests applications for studies designed to develop and test multi-level interventions to prevent opioid misuse, opioid use disorder, and co-occurring conditionsby intervening on social determinants of health (SDOH).This initiative aims to build an evidence base for multi-level interventions that target malleable factors and conditions affecting the social context. Applications must seek to reduce health inequities in a U.S. population or population subgroup affected by the opioid crisis by studyingthe effects of a theory driven, multi-level intervention on the prevention of opioid misuse/opioid use disorder and co-occurring conditions. Such conditions could include mental health conditions and/or suicide, and may alsoinclude other substance use and substance use-related outcomes. The research project must examinethe mechanisms by which the interventions exert their effects, and conduct economic analyses to inform decisions about adoption of strategies. Investigators should study interventions that are sustainable and easily taken to scale if effective.

Funding Opportunity PAR-22-070 from the NIH Guide for Grants and Contracts. The National Eye Institute (NEI) Audacious Goal Initiative (AGI) is an effort to push the boundaries of vision science and restore vision through regeneration of cells in the retina. AGI research specifically targets photoreceptors (PRCs) and retinal ganglion cells (RGCs) in the eye. Photoreceptors often called rods and cones are cells in the retina that, when stimulated by light, generate signals the brain perceives as images. The retinal ganglion cells carry these signals from the photoreceptors to the brain. Although there has been some success in regenerating retinal neurons and connections in fish, mice, and other systems, the ultimate goal of the AGI is to restore vision in humans.

Funding Opportunity RFA-HL-23-008 from the NIH Guide for Grants and Contracts. The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.

Funding Opportunity PAR-22-064 from the NIH Guide for Grants and Contracts. NIMHD intends to support innovative multi-disciplinary (such as behavioral, biological, environmental, social, cultural) and multi-level (e.g., patient, clinician, interpersonal, community) research designed to understand and address how optimizing patient-clinician relationships/communication affects health care outcomes for patients from populations with health disparities.

Funding Opportunity RFA-MH-22-150 from the NIH Guide for Grants and Contracts. The proposed FOA would solicit applications focused on enhancing the potency of established adolescent mental health treatments through the use of developmentally informed and theoretically grounded JITAIs. While JITAIs could be applied to established interventions across the lifespan, we propose focusing specifically on adolescence - a developmental period characterized by heightened risk for new onset or worsening mental illness, poor engagement with face-to-face interventions, and peak engagement with technology. JITAIs have the potential to capitalize on adolescents near ubiquitous use of technology to facilitate symptom reduction and behavior change by providing content via an intrinsically motivating platform, facilitating skills practice in ecologically-valid contexts, tailoring the intervention to match the adolescents needs and preferences, providing in-the-moment feedback and reinforcement, and scaffolding adolescents in real time to mitigate impairments. Recent technological advancements have greatly improved the feasibility of delivering JITAIs, and these interventions have shown promise in a variety of health and addiction domains. Yet, no studies of JITAIs for adolescent mental disorders have been published to date, highlighting the need for research in this emerging area of intervention science.

Funding Opportunity PAR-22-047 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.

Notice NOT-HD-21-047 from the NIH Guide for Grants and Contracts

Notice NOT-EY-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-AT-22-001 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-008 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-017 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-065 from the NIH Guide for Grants and Contracts

Notice NOT-TR-22-008 from the NIH Guide for Grants and Contracts

Notice NOT-TR-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-TR-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-RM-22-004 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-070 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-012 from the NIH Guide for Grants and Contracts

Notice NOT-ES-22-001 from the NIH Guide for Grants and Contracts